Viking Therapeutics Reports Increased R&D, Advances Key Programs to Phase 3, Secures Manufacturing, and Maintains Strong Liquidity

summarizeSummary

Viking Therapeutics' annual report highlights a significant increase in R&D expenses and net loss due to accelerated clinical development, with key obesity and NASH programs advancing to Phase 3 and manufacturing secured, supported by a strong cash position.

check_boxKey Events

• Significant Increase in R&D Expenses

  Research and development expenses surged to $345.0 million in 2025, a substantial increase from $101.6 million in 2024, reflecting accelerated clinical development across multiple programs.

• Advancement of VK2735 Obesity Programs

  The company initiated Phase 3 clinical studies for its subcutaneous VK2735 formulation and reported positive Phase 2 results for the oral formulation, with Phase 3 oral studies planned for Q3 2026. An exploratory Phase 1 maintenance dosing study also completed enrollment.

• Positive VK2809 NASH/MASH Data

  Viking Therapeutics announced positive 52-week histologic data from the VOYAGE Phase 2b study for VK2809, demonstrating significant NASH resolution (up to 75%) and fibrosis improvement (up to 57%).

• Secured VK2735 Manufacturing Capacity

  Multi-year manufacturing agreements were signed with Corden Pharma in March 2025, securing dedicated capacity for API and finished product supply for VK2735, including 100 million autoinjectors and over 1 billion oral tablets annually.

auto_awesomeAnalysis

Viking Therapeutics' 2025 annual report details a significant increase in R&D expenses and net loss, primarily driven by the accelerated advancement of its clinical pipeline. This substantial investment is focused on key programs like VK2735 for obesity (subcutaneous and oral formulations) and VK2809 for NASH/MASH, both of which have shown positive clinical data and are progressing to or are in Phase 3 trials. The company has also secured critical manufacturing agreements for VK2735, a crucial step towards potential commercialization. While the increased losses are notable, they are a direct result of these strategic development efforts. The strong cash position provides a solid financial runway, mitigating immediate liquidity concerns. The positive outcome in the trade secret litigation further de-risks intellectual property, although appeals are pending. The COO's retirement is a minor executive change.